Oct 03, 2023 / 03:00PM GMT
Keay Nakae - Chardan Capital Markets, LLC - Analyst
My pleasure to introduce our next guest from Dyne Therapeutics, CEO, Josh Brumm; and CSO, Dr. Oxana Beskrovnaya. Thank you so much for being with us. Josh, maybe to start, can you provide a brief overview of the company, how you're differentiated in your key accomplishments in 2023 year to date?
Josh Brumm - Dyne Therapeutics, Inc. - CEO
Yeah. Thanks, Keay, and thanks again for the invitation to be here today. We will be making some forward-looking statements, so just, as always, refer to the SEC filings on those matters.
Look. For Dyne, it is a very exciting time. We -- this month marks my four-year anniversary at the company. Over the past four years, we've been putting together our focus on delivering targeted oligos to muscle, and that's been driven by our FORCE platform. Many of you know, we have a fragment antibody, a clinically validated linker, and we cycle payloads based on the genetic basis of the disease.
We're targeting to really focus on our core three programs in the portfolio
Dyne Therapeutics Inc at Chardan Genetic Medicines Conference Transcript
Oct 03, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers